MSH2 and neoplasm: In addition, the AUC (4–48 h) for [111In]DOTA-Phospho-MSH2-9 was 1.81, i.e., the tumor-to-kidney ratio was threefold higher than that of [111In-DOTA-Nle4,Asp5,d-Phe7,Lys11(Suc)]-α-MSH4-11-carboxylate exhibiting an AUC (4–48 h) of 0.62 (14).